03. Pharmacotherapy for Opioid Use Disorder

MODULE 2 | SECTION 3 OF 5

Pharmacotherapy for Opioid Use Disorder

Reset Learningobjective Icon 01

Learning objective

Demonstrate the importance of access to naloxone and medications for the
treatment of OUD.

Medications for Opioid Use Disorder Save Lives

Imagine if there was a safe, effective vaccine for HIV. Would you not give the vaccine to your patients because it would encourage people to practice unsafe sex?

Of course not. However, we have effective treatments for opioid use disorder (OUD) but these treatments are not in widespread use. Why?

Let’s briefly review various pharmacotherapies available to treat OUD and the data that support their use. There are several effective, safe medicines to treat OUD.

Buprenorphine, methadone and naltrexone are often referred to as medication-assisted treatment (MAT). However, the term “medication assisted” may increase stigma towards these life-saving treatments as it reinforces the false notion that appropriately prescribing medication for treatment “replaces one addiction for another.”1 Insulin is not medication-assisted treatment for diabetes. Rather, insulin is medication for the treatment of diabetes. Similarly, buprenorphine, methadone, and naltrexone are medications approved for the treatment of OUD. Medications that treat OUD are safe, effective, and save lives.2

 

Medications approved for the treatment of OUD:

  • ● Decrease mortality3,4

  • ● Reduce risk of infection, including HIV and HCV5,6

  • ● Increase engagement in treatment and reduces opioid use following release from incarceration7

Reset Module2 Section3 Medicationtotreadoud V1 01
Reset Module2 Section3 Medicationtotreadoud V1 02

Medications for Opioid Use Disorder (MOUD) are Endorsed by Many Medical Professional Societies

“Medication-based treatment is effective across all treatment settings studied to date. Withholding or failing to have available… medication for the treatment of opioid use disorder in any care setting is denying appropriate medical treatment.”

 

National Academy of Medicine Consensus Report, 2019

If These Medications Work, Why Don’t We See More Widespread Use?

Buprenorphine and methadone cut overdose death rates in half while decreasing drug use, decreasing HIV and hepatitis C transmission, and improving patient retention in treatment. Buprenorphine in particular has a very low risk of addiction, due to the way the drug works in the brain.

Drug-free treatment is not as effective as medications for OUD in preventing deaths. Recurrences of use and deaths are common as patients try to maintain abstinence, since strong cravings persist for years after last use.9

Twelve step and other abstinence-based approaches may be helpful for many substance use disorders, but they only succeed in 10% to 15% of people with OUD when used alone. MOUD is effective for 50% to 80% of patients with OUD.9

Most people who take illicit buprenorphine are taking it to avoid withdrawal, detoxification or relapse prevention and not to get “high”.10 Buprenorphine is a long-acting opioid receptor partial agonist– this characteristic makes it very difficult to get any euphoric effect from buprenorphine. When it is sold on the street, it is most commonly used to treat withdrawal symptoms in patients with low access to medical treatment.10 People who have used illegal buprenorphine are more likely to stay in treatment once they start treatment.8

Increased access to naloxone reduced mortality and has not been shown to increase drug use.11

How Do Medications For OUD Work?

The three medications widely used for the treatment of OUD are methadone, buprenorphine and naltrexone. In addition, naloxone is used to reverse an opioid overdose.12

Methadone

  • Long-acting opioid that reduces cravings and eliminates withdrawal

  • Patient typically attends clinic daily and takes the medication while supervised by staff

  • Dispensed as a liquid

  • Minimal euphoria

  • Full agonist at opioid receptors

  • Overdose risk

 

Buprenorphine (Suboxone® or Subutex®)

  • Reduces cravings and treats withdrawal

  • Usually given in a one-week supply, so no need to go daily to a clinic to obtain medicine

  • Most commonly given as a sublingual film

  • Minimal euphoria (less than methadone)

  • Partial agonist at opioid receptors

  • Low overdose risk. (Use of concurrent benzodiazepines can increase that risk.)

 

Naltrexone (Vivitrol®)

  • Reduces cravings and blocks opioid effects

  • Typically administered as a once-monthly injection

  • No euphoria

  • Antagonist at opioid receptors

  • No overdose risk

  • Expensive

  • Requires a 7 to 10 day abstinence period from opioids before it can be started

Naloxone (Narcan®)

  • Rapidly reverses opioid overdoses

  • Administered in the outpatient setting as an intranasal spray or injection

  • No euphoria

  • Antagonist at opioid receptors

  • No overdose risk

  • Often carried by first responders and laypeople in the community

How OUD Medications Work in the Brain

Drag and drop a medication used to treat OUD to the empty opioid receptor to learn how it works.

Partial agonist:
generates limited effect

REFERENCES

  1. 1-Ashford R, Brown A, Curtis B. Substance use, recovery, and linguistics: The impact of word choice on explicit and implicit bias. Drug and Alcohol Dependence. 2018;189:131-138. doi:10.1016/j.drugalcdep.2018.05.005

 

  1. 2-Committee on Medication-Assisted Treatment for Opioid Use Disorder, Board on Health Sciences Policy, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. Medications for Opioid Use Disorder Save Lives. (Leshner AI, Mancher M, eds.). Washington, D.C.: National Academies Press; 2019. doi:10.17226/25310

 

  1. 3-Larochelle M, Bernson D, Land T. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Annals of Internal Medicine. June 2018. doi:10.7326/M17-3107

 

  1. 4-Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. doi:10.1136/bmj.j1550

 

  1. 5-Metzger DS, Donnell D, Celentano DD, et al. Expanding Substance Use Treatment Options for HIV Prevention With Buprenorphine–Naloxone: HIV Prevention Trials Network 058. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2015;68(5):554-561. doi:10.1097/QAI.0000000000000510

 

  1. 6-Bruce RD, Kresina TF, McCance-Katz EF. Medication-assisted treatment and HIV/AIDS: aspects in treating HIV-infected drug users: AIDS. 2010;24(3):331-340. doi:10.1097/QAD.0b013e32833407d3

 

  1. 7-Moore KE, Roberts W, Reid HH, Smith KMZ, Oberleitner LMS, McKee SA. Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review. Journal of Substance Abuse Treatment. 2019;99:32-43. doi:10.1016/j.jsat.2018.12.003

 

  1. 8-Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An International Review. Curr Drug Abuse Rev. 2011;4(1):28-41.

 

  1. 9-Schwartz RP, Gryczynski J, O’Grady KE, et al. Opioid Agonist Treatments and Heroin Overdose Deaths in Baltimore, Maryland, 1995–2009. Am J Public Health. 2013;103(5):917-922. doi:10.2105/AJPH.2012.301049

 

  1. 10-Carroll JJ, Rich JD, Green TC. The More Things Change: Buprenorphine/naloxone Diversion Continues While Treatment Remains Inaccessible. Journal of Addiction Medicine. 2018;12(6):459-465. doi:10.1097/ADM.0000000000000436

 

  1. 11-McClellan C, Lambdin BH, Ali MM, et al. Opioid-overdose laws association with opioid use and overdose mortality. Addictive Behaviors. 2018;86:90-95. doi:10.1016/j.addbeh.2018.03.014

 

  1. 12-Providers Clinical Support System. MAT Waiver Eligibility Training. 2018.

Leave a Comment